Central Serous Chorioretinopathy or a stressful lifestyle predisposes to the disease? - review of the current literature
DOI:
https://doi.org/10.12775/JEHS.2023.13.03.034Keywords
central serous chorioretinopathy, serous retinal detachment, optical coherence tomographyAbstract
Central serous chorioretinopathy (CSCR) is a disease characterized by serous detachment of the neurosensory retina in the macular area, caused by increased choroidal vascular permeability. The disease is more common in young and middle-aged men (20-50 years old), it has been shown to be highly correlated with an increased level of stress in patients. Other risk factors for the central serous chorioretinopathy are: type A personality (ambitious, nervous and emotional people), use of steroids, Cushing’s syndrome, helicobacter pylori infection, gastroesophageal reflux, hypertension, sleep apnea. The disease leads to visual impairment: metamorphopsia, blurred vision, color vision impairment, impaired contrast and vision in the dark. CSCR diagnostics include funduscopic examination of the eye through the Volk lens revealing focus of circular retinal elevation, optical coherence tomography (OCT), which is a quick and non-invasive test that allows the diagnosis and monitoring of the disease. In the past, the diagnosis was based on fluorescein angiography, the dye spilling out fills the detachment space, revealing the leak center. In most cases the shunt stops spontaneously and spontaneous resorption of the subretinal fluid occurs without the need for treatment. The chronic form of CSCR ongoing more than 4 months requires initiation of therapeutic procedures. The first- line treatment is laser therapy. Micropulse laser therapy of the retina stimulates the pigment epithelium to produce anti-angiogenic factors and inhibit the inflammatory process, as a consequence, the resorption of the subretinal fluid occurs with minimal damage to the retina.
References
Tsai DC, Chen SJ, Huang CC, et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One. 2013 Jun 24;8(6):e66858. doi: 10.1371/journal.pone.0066858. PMID: 23826160; PMCID: PMC3691239.
Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967 Mar;63(3):Suppl:1-139. PMID: 6019308.
Rejdak R, Rękas M.: Siatkówka i ciało szkliste. 2018-2019 BSCS; American Academy of Ophthalmology. Edra Urban & Partner, Wrocław 2020.
Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008 Mar;86(2):126-45. doi: 10.1111/j.1600-0420.2007.00889.x. Epub 2007 Jul 28. PMID: 17662099.
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008 Jan;115(1):169-73. doi: 10.1016/j.ophtha.2007.02.032. PMID: 18166410.
Gäckle HC, Lang GE, Freissler KA, Lang GK. Chorioretinopathia centralis serosa. Klinische, fluoreszeinangiographische und demographische Aspekte [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Ophthalmologe. 1998 Aug;95(8):529-33. German. doi: 10.1007/s003470050310. PMID: 9782727.
Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987 Summer;7(2):111-31. doi: 10.1097/00006982-198700720-00009. PMID: 3306853.
Bousquet E, Dhundass M, Lehmann M, et al. Shift Work: A Risk Factor for Central Serous Chorioretinopathy. Am J Ophthalmol. 2016 May;165:23-8. doi: 10.1016/j.ajo.2016.02.012. Epub 2016 Feb 22. PMID: 26915576.
Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003 Jun;87(6):704-8. doi: 10.1136/bjo.87.6.704. PMID: 12770965; PMCID: PMC1771713.
Haimovici R, Koh S, Gagnon DR, et al. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004 Feb;111(2):244-9. doi: 10.1016/j.ophtha.2003.09.024. PMID: 15019370.
Gawecki M, Groszewska E. Central serous chorioretinopathy and pregnancy. Arch Ophthalmol. 1993.
Tripathy K. Is Helicobacter pylori the culprit behind central serous chorioretinopathy? Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):2069-2070. doi: 10.1007/s00417-016-3418-7. Epub 2016 Jun 30. PMID: 27364118.
Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996 Dec;103(12):2070-9; discussion 2079-80. doi: 10.1016/s0161-6420(96)30386-2. PMID: 9003341.
Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004 Jun;137(6):1096-100. doi: 10.1016/j.ajo.2004.01.054. PMID: 15183795.
Gupta A, Tripathy K. Central Serous Chorioretinopathy. 2022 Aug 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 32644399.
Van Rijssen TJ, van Dijk EHC, Yzer S,et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003. Epub 2019 Jul 15. PMID: 31319157.
Kim HC, Cho WB, Chung H. Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography. Korean J Ophthalmol. 2012 Oct;26(5):347-54. doi: 10.3341/kjo.2012.26.5.347. Epub 2012 Sep 24. PMID: 23060721; PMCID: PMC3464318.
Kleinberger AJ, Patel C, Lieberman RM, Malkin BD. Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: a case report and review of the literature. Laryngoscope. 2011 Sep;121(9):2034-7. doi: 10.1002/lary.21967. Epub 2011 Aug 16. PMID: 22024860.
Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019 Jul 25;19(1):160. doi: 10.1186/s12886-019-1171-5. PMID: 31345183; PMCID: PMC6659242.
Gawęcki M. Centralna Surowicza Choroidopatia - choroba o różnych obliczach. Medycyna Praktyczna. 02/11/2017.
Gawęcki M. Diagnostyka różnicowa zwyrodnienia plamki związanego z wiekiem i centralnej surowszej chorioretinopatii. Okulistyka Kwartalnik Medyczny. 2021 (2): 29-41.
Zagórski Z. Oksfordzki podręcznik okulistyki. Czelej 2009.
Chhablani J, Cohen FB; Central Serous Chorioretinopathy International Group. Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. Ophthalmol Retina. 2020 Nov;4(11):1043-1046. doi: 10.1016/j.oret.2020.07.026. PMID: 33131671.
Van Dijk EHC, Fauser S, Breukink MB, et al. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018 Oct;125(10):1547-1555. doi: 10.1016/j.ophtha.2018.04.021. Epub 2018 Jun 14. PMID: 29776672.
Scholz P, Altay L, Fauser S. A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Adv Ther. 2017 Jul;34(7):1528-1555. doi: 10.1007/s12325-017-0559-y. Epub 2017 May 24. PMID: 28540655; PMCID: PMC5504253.
Chung YR, Kim JW, Song JH, Park A, Kim MH. Twelve - month efficacy of intravitreal bevacizumab injection for chronic, atypical, or recurrent serous choriiretinopathy. Retina 2019; 39(1). Doi:10.1097/IAE.0000000000001917 PMID: 29077604.
Schworm B, Luft N, Keidel LF, et al. Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefes Arch Clin Exp Ophthalmol. 2020 May;258(5):1013-1021. doi: 10.1007/s00417-020-04623-w. Epub 2020 Feb 28. PMID: 32112141.
Bahadorani S, Maclean K, Wannamaker K, et al. Treatment of central serous chorioretinopathy with topical NSAIDs. Clin Ophthalmol. 2019 Aug 15;13:1543-1548. doi: 10.2147/OPTH.S202047. PMID: 31616132; PMCID: PMC6699520.
Pichi F, Carrai P, Ciardella A, et al. Central Serous Chorioretinopathy Study Group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017 Oct;37(5):1115-1125. doi: 10.1007/s10792-016-0377-2. Epub 2016 Oct 18. PMID: 27757733.
Kurup SK, Oliver A, Emanuelli A, et al Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina. 2012 Nov-Dec;32(10):2096-101. doi: 10.1097/IAE.0b013e31825dd281. PMID: 22718154.
Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002 Sep;109(9):1723-5. doi: 10.1016/s0161-6420(02)01157-0. PMID: 12208723.
Caccavale A, Romanazzi F, Imparato M, et al Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010 Aug 9;4:899-903. doi: 10.2147/opth.s12583. PMID: 20714368; PMCID: PMC2921298.
Tripathy K. Is Helicobacter pylori the culprit behind central serous chorioretinopathy? Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):2069-2070. doi: 10.1007/s00417-016-3418-7. Epub 2016 Jun 30. PMID: 27364118.
Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013 Mar-Apr;58(2):103-26. doi: 10.1016/j.survophthal.2012.07.004. PMID: 23410821; PMCID: PMC3574296.
Scholz P, Ersoy L, Boon CJ, Fauser S. Subthreshold Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy. Ophthalmologica. 2015;234(4):189-94. doi: 10.1159/000439600. Epub 2015 Sep 26. PMID: 26406874.
Mohabati D, Boon CJF, Yzer S. Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy. Clin Ophthalmol. 2020 Apr 29;14:1165-1175. doi: 10.2147/OPTH.S242926. PMID: 32425502; PMCID: PMC7196815.
Da Pozzo S, Iacono P, Arrigo A, Battaglia Parodi M. The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy. Pharmaceuticals (Basel). 2021 Jan 29;14(2):105. doi: 10.3390/ph14020105. PMID: 33572948; PMCID: PMC7912149.
Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset. J Clin Med. 2019 Sep 6;8(9):1398. doi: 10.3390/jcm8091398. PMID: 31500100; PMCID: PMC6780961.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ewelina Dybała, Izabela Dybała-Przygrodzka, Iwona Cuber, Magdalena Mazurek, Edyta Białowąs, Artur Aghadi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 682
Number of citations: 0